Compare PCVX & MOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | MOH |
|---|---|---|
| Founded | 2013 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 8.9B |
| IPO Year | 2020 | 2002 |
| Metric | PCVX | MOH |
|---|---|---|
| Price | $62.79 | $147.82 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 13 |
| Target Price | $88.25 | ★ $157.15 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.92 |
| Revenue | N/A | ★ $45,426,000,000.00 |
| Revenue This Year | N/A | $2.36 |
| Revenue Next Year | N/A | $5.23 |
| P/E Ratio | ★ N/A | $16.78 |
| Revenue Growth | N/A | ★ 11.75 |
| 52 Week Low | $28.09 | $121.06 |
| 52 Week High | $65.00 | $340.88 |
| Indicator | PCVX | MOH |
|---|---|---|
| Relative Strength Index (RSI) | 65.54 | 54.11 |
| Support Level | $42.30 | $140.20 |
| Resistance Level | $65.00 | $152.27 |
| Average True Range (ATR) | 2.28 | 6.05 |
| MACD | 0.62 | 1.79 |
| Stochastic Oscillator | 95.44 | 78.21 |
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Molina provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in just four states—California, New York, Texas, and Washington—account for over half of its enrollees.